Related Experiment Videos
Plasma exchange in refractory cutaneous vasculitis.
A N Turner1, S Whittaker, I Banks
1Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, U.K.
The British Journal of Dermatology
|March 1, 1990
Summary
Plasma exchange therapy shows significant promise for treating severe cutaneous vasculitis. This treatment led to substantial improvement in most patients with refractory disease, offering a valuable therapeutic option.
Area of Science:
- Immunology
- Dermatology
- Nephrology
Background:
- Cutaneous leucocytoclastic vasculitis is a challenging condition.
- Intractable cases require novel therapeutic approaches.
Purpose of the Study:
- To evaluate the efficacy and safety of plasma exchange therapy in patients with severe refractory cutaneous vasculitis.
Main Methods:
- Eight patients with intractable cutaneous leucocytoclastic vasculitis underwent plasma exchange therapy.
- Treatment duration varied, with some patients receiving intermittent plasma exchange for up to 12 years.
Main Results:
- Seven out of eight patients demonstrated improvement, with five experiencing substantial benefits.
- Long-term intermittent plasma exchange proved successful in four patients.
- One case of hepatitis B was noted, potentially linked to fresh frozen plasma, with no other major adverse events reported.
Conclusions:
- Plasma exchange is a potentially valuable therapeutic option for severe, refractory cutaneous vasculitis.
- The treatment demonstrates a favorable safety profile for long-term management.